logo

Aveo Pharmaceuticals, Inc. (AVEO)



Trade AVEO now with
  Date
  Headline
4/16/2021 7:03:32 AM AVEO Oncology Appoints Kevin Cullen To Board
3/23/2021 10:38:13 PM AVEO Oncology Prices Public Offering Of 6 Mln Shares At $8.00/shr
3/22/2021 4:10:42 PM AVEO Announces Proposed Public Offering Of Common Stock
3/22/2021 7:15:07 AM AVEO Oncology Announces U.S. Commercial Availability Of FOTIVDA For Relapsed Or Refractory Advanced Renal Cell Carcinoma
3/15/2021 7:03:33 AM AVEO Oncology To Regain Its Rights To AV-203 Outside Of North America
3/12/2021 7:06:19 AM AVEO Collaborates With BMY To Evaluate FOTIVDA-OPDIVO In Phase 3 TiNivo-2 Trial In IO Relapsed Renal Cell Carcinoma
1/20/2021 7:07:39 AM AVEO Oncology Announces Commitment For Incremental $10 Mln Loan In Addition To Current Tranched
1/15/2021 8:18:56 AM AVEO Oncology Announces Results From Phase 1b Portion Of DEDUCTIVE Study Of Tivozanib In Combination With IMFINZI
1/7/2021 7:29:55 AM AVEO Oncology Highlights Recent Progress And Outlines 2021 Outlook
9/8/2020 7:05:56 AM AVEO Oncology Regains Full Global Rights To Ficlatuzumab
6/16/2020 11:09:58 PM AVEO Oncology Prices Underwritten Public Offering Of 8.50 Mln Shares At $5.25/shr
6/1/2020 1:37:01 PM AVEO Oncology Says FDA Accepts Filing Of NDA For Tivozanib As Treatment Of Relapsed Or Refractory Renal Cell Carcinoma
5/29/2020 7:09:54 AM AVEO Oncology Announces Phase 1b/2 DEDUCTIVE Study Of FOTIVDA In Combination With IMFINZI Advances To Phase 2
5/29/2020 7:05:33 AM AVEO Oncology Announces TIVO-3 Final Overall Survival Results Featured At ASCO 2020 Virtual Scientific Program A